Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell Carcinoma

Description

ODYSSEY RCC is a prospective, observational Phase IV study is to understand the cancer management and health-related quality of life in patients with mRCC in routine real-world clinical practice in the United States, including both community and academic treatment settings.

Conditions

Metastatic Renal Cell Carcinoma

Talk to us

Study Overview

On this page

Study Details

Study overview

ODYSSEY RCC is a prospective, observational Phase IV study is to understand the cancer management and health-related quality of life in patients with mRCC in routine real-world clinical practice in the United States, including both community and academic treatment settings.

Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell Carcinoma (ODYSSEY RCC)

Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell Carcinoma

Condition
Metastatic Renal Cell Carcinoma
Intervention / Treatment

-

Contacts and Locations

Iowa City

State University of Iowa, Iowa City, Iowa, United States, 52242

Kansas City

University of Kansas Medical Center, Kansas City, Kansas, United States, 66160

Baltimore

The Johns Hopkins University, Baltimore, Maryland, United States, 21205

Ann Arbor

The Regents of the University of Michigan, Ann Arbor, Michigan, United States, 48109

Rochester

Mayo Clinic, Rochester, Minnesota, United States, 55905

Durham

Duke University, Durham, North Carolina, United States, 27710

Danville

Geisinger Clinic, Danville, Pennsylvania, United States, 17822

Pittsburgh

University of Pittsburgh, Pittsburgh, Pennsylvania, United States, 15260

Dallas

The University of Texas Southwestern Medical Center, Dallas, Texas, United States, 75390

Salt Lake City

University of Utah, Salt Lake City, Utah, United States, 84112

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Age 19 or over at time of informed consent.
  • * Diagnosis of metastatic renal cell cancer (mRCC) with less than or equal to (≤) 6 weeks of first-line systemic therapy for mRCC.
  • 1. Prior surgery and radiation therapy are permitted.
  • 2. Prior neoadjuvant and adjuvant therapy for non-metastatic renal cell carcinoma are permitted.
  • 3. Patients currently not on therapy and being observed are permitted.
  • * Evidence of signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the study.
  • * Ability to comply with completion of PROs
  • * Patients being treated for metastatic solid tumors other than mRCC are excluded. Non-cytotoxic oral agents for adjuvant or maintenance therapy of other cancers are permitted.
  • * Patients who are not intending to undergo follow up care at a study site within PCORnet

Ages Eligible for Study

19 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Duke University,

Daniel George, MD, PRINCIPAL_INVESTIGATOR, Duke University

Study Record Dates

2026-07